SEQUENT SCIENTIFIC :
++++++++++++++++

Price moving in a upward channel. Gets halted
by the coflunce and moves in a trading range.
Price at key weekly support with narrow spread
and falling volumes.

Upside of 20 - 30 %

#pricenpedia #stockmarket

Sequent 2.0 for vision 2025.

Change in dynamics in last 5 quarters has enabled them to aim big in next 5 years.

A thread of Concall excerpt discussing how seeds are sown for a strong future.
@unseenvalue

Mar, 2020:
Carlyle Acquiring stake gives them a strong backbone which enables them to think about entering US or China market and lot of other optionality.

Filed First injectable (Tulathromycin) for US market.

Initiated CDMO business (optionality)

June, 2020
Multi-year agreement with Zoetis to market & distribute their ruminant portfolio in India. Being Partner of Zoetis provides gloabl image & helps to acquire their CDMO customer in future.

CDMO is very niche initiative targeting only veterinary API customers.

Sep, 2020:
Acquired 40% of Provet (Turkey Subsidiary, extremely profitable business) making it a wholly owned subsidiary which will improve their bottomline.

Hired Stonehaven as consultant to become top 10 animal healthcare company, dreaming big.

Dec, 2020:
CDMO model initiated with one of the largest AH player, 2 products under execution.

Sequent has top-notch management. There are best practices brought in by Carlyle Group but even more valuable is CEO Manish Gupta. We place immense faith in Gupta who has been CEO since founding & has done outstanding job steering co to becoming Indian MNC https://t.co/Z0UxAAJMJX

SEQUENT 🐕💊 Annual Report

Having multiple facilities accredited with certifications from the best authorities from globe is a hidden moat in itself... 10-20% pop and then retracement should not shake confidence... Business focus and longevity should build conviction
🐶🐱🐴🐮🐷🐑

@unseenvalue @soicfinance

#sequent

Positional trade

Stock is back in the Triangle

Breakout above 285 levels

We may see 320/340 levels

Positional targets are for 500+ in next 6 months

@drprashantmish6
@unseenvalue
@soicfinance

Stocks to watch

#nifty50
#trading
#StocksToWatch

Animal Pharma innovators are actively looking at competent, reliable API/CDMO partners.

"We predict that the sourcing, partnering, development and funding of innovation will be more transformational and significant the next five years than ever before in animal health" - #Elanco

So many updates on #SequentScientific Results, almost none focus on the most important metric

Net profit before tax and exceptional items (True Cash earned by the company) increase by ~55% YoY

ROCE now above 20% and PAT increase by 36.5% are signs of Operating Leverage

Before Op Leverage kicked in for Laurus, its ROCE was in ~14%

The Advisor onboarded created the animal healthcare business for Boehringer Ingelheim (~2nd largest animal healthcare business in the world with net sales of ~4.5 Billion+ and presence in over 150 countries

Look for qualitative insights in a business, quantitative insights are just ~10% of the work

Global Animal pharma market($ 50.89 billion) is expected to grow much faster than human pharma. CAGR 8.8% in 7 to 8 years

API account for 20% market

Innovators are going Asset light
It's a huge opportunity for the first mover in CDMO (Hikal)

And in formulation & API(sequent)

If your salary / incentives are not dependent on the next quarter earnings, just relax!

No one has any idea where the stock is going in the short term. Your paid advisors definitely haven't got any idea. They're just making it up, so you stay with them.

Key word :: quarter